Pulmonary Central, Author at PulmCCM
Advertisement

Pulmonary Central

Pulmonary Central was the previous name for the PulmCCM blog. The PulmCCM team writes the posts under this moniker. Read the About page for more of the PulmCCM story.

Feb 222017
 
Simple qSOFA score predicts sepsis as well as anything else

Sepsis is sneaky. Physicians, nurses, and epidemiologists struggle to accurately identify patients with sepsis in the emergency department, hospital ward, and in data sets. The so-called SIRS criteria were abandoned as insensitive and nonspecific in the most recent iteration of sepsis care. Sepsis is instead now defined as “life-threatening organ dysfunction caused by a dysregulated [… read more]

Feb 152017
 
Oxygen saturation in critical illness: could low-normal be best?

Oxygen is essential for life, but by forming superoxides and free radicals, supplemental oxygen can also inflict damage on lung and other body tissues. The sweet spot for oxygen delivery in critically ill patients is unknown, but increasing evidence suggests that when it comes to blood oxygen saturation during critical illness, “normal” levels might actually [… read more]

Feb 092017
 
Reslizumab (CINQAIR) worked as add-on treatment for severe asthma with eosinophilia

Reslizumab (CINQAIR) is a humanized, anti-IL-5 biologic agent approved by FDA in March 2016 as add-on treatment for asthma with peripheral blood eosinophilia, uncontrolled by usual treatments. In two randomized trials, reslizumab improved lung function and asthma symptoms in patients meeting these criteria. Patients without high eosinophil count in peripheral blood did not experience clinically [… read more]

Feb 082017
 
Early renal replacement therapy in critical illness did not improve outcomes (AKIKI)

When is the optimal time to initiate renal-replacement therapy in the ICU? Patients with acute renal failure (a.k.a. acute kidney injury or AKI) in the ICU experience worse outcomes than patients who do not. As the kidneys shut down, toxic electrolytes and metabolic waste products build up in the blood. Intuition says — screams, really [… read more]

Feb 012017
 
Passive leg raise test: helpful maneuver, or ICU parlor trick?

Patients who arrive at the hospital with hypotension will almost all receive intravenous fluid resuscitation (one hopes). When signs of hypoperfusion occur later in a patient’s hospital course, it can be much harder to decide if additional fluid will be helpful. Physical exam is unreliable, and no available technology can accurately identify how much water is [… read more]

Feb 012017
 
Advanced Critical Care Simulation Conference: Feb 17-18 in Phoenix (Register)

Register Now! PulmCCM is not affiliated with Banner University or the University of Arizona. SHARPEN YOUR LIFE-SAVING CRITICAL-CARE SKILLS Focusing on the clinical situations of highest concern to bedside intensivists, including the emergency evaluation of the patient with undifferentiated shock, the failed airway, refractory ARDS and obstetrical code arrest, this conference will bring participants up-to-date [… read more]

Jan 282017
 
Last chance to apply for the ALiEM Faculty Incubator

Junior faculty members: Looking for a way to bolster your academic credentials and engage/network with an established community of medical educators? The ALiEM (Academic Life in Emergency Medicine) Faculty Incubator is a yearlong online faculty development program (limited to 30 participants yearly), nearly exclusively done with online asynchronous interactions through the Slack platform. The incubator [… read more]

Jan 182017
 
Azithromycin was no help in asthma exacerbations (AZALEA)

Adding azithromycin to usual treatment for asthma exacerbations in adults did not improve asthma symptoms or speed their resolution, investigators reported in the AZALEA randomized clinical trial. Patients getting azithromycin also had no improvement in lung function. Azithromycin is known to have some activity against viruses that infect bronchial cells; viruses are causative or contributory [… read more]

Dec 162016
 
Inferior vena cava filters are overused. What's the harm?

Inferior vena cava filters (IVCF) are placed to prevent deep venous thromboses (DVT) from traveling to the heart and lungs, causing pulmonary embolism (PE). IVC filters’ rationale makes sense, but despite their wide use, the benefits and risks of IVCF remain unclear. With about 50,000 IVC filters placed annually in the U.S., that’s a lot of unclarity. [… read more]

Dec 072016
 
New 2017 GOLD Guidelines for COPD Released

The Global Initiative for Obstructive Lung Disease (GOLD – because GIOLD sounded weird) is an international collaboration of experts in chronic obstructive pulmonary disease (COPD). Every so often the GOLD gang releases another update of their standard-setting GOLD guidelines. (Read PulmCCM’s 2014 GOLD guideline review and our COPD Review.) Get the full 2017 GOLD guidelines or the 36 page [… read more]

Dec 012016
 
Targeted molecular therapies for non-small cell lung cancer: Clinical Update

For too long, treatment for advanced non-small cell lung cancer was brutally simple: platinum chemotherapy and a trip to the attorney to get one’s affairs in order. Fortunately for patients, it’s not quite so straightforward anymore. Effective targeted molecular therapies for non-small cell lung cancer are now available, often taken orally with fewer side effects than traditional cytotoxic [… read more]

Nov 252016
 
Life-sucking power of electronic health records measured, reported, lamented

Feel like you spend twice as much time on your electronic health record as you do with patients? You may be doing better than half of your colleagues. In a new work study funded by the American Medical Association, researchers observed 57 physicians in internal medicine, family medicine, cardiology, and orthopedics over hundreds of hours. They discovered [… read more]

Nov 232016
 
Breo Ellipta beat usual care for COPD in real-world study

GlaxoSmithKline recently got a boost for fluticasone-furoate + vilanterol (Breo Ellipta), its new once-daily COPD maintenance inhaler. Patients with COPD randomized to Breo Ellipta (called Relvar Ellipta in Europe), instead of usual care, had 8% fewer exacerbations and no increased risk for serious adverse events over one year. GSK presented the data at the ERS [… read more]

Nov 182016
 
Does intensive rehab and physical therapy in the ICU really help?

Every year, over a million people in the U.S. suffer respiratory failure requiring mechanical ventilation. They experience enormous catabolic stress, extended periods of inactivity, and usually go without their usual caloric intake. It’s no surprise that many are rendered profoundly debilitated by the experience. For many, this weakness and loss of muscle mass represents a second [… read more]

Nov 172016
 
Older transfused blood as good as fresh (INFORM)

What’s the shelf life of human blood? Like the milk in your fridge, stored donated human blood has an expiration date: currently it’s 42 days, set by the FDA. But is fresher blood actually better? As with ordering wine by the glass, should patients about to be transfused blood ask for “whatever was opened most recently”? There’s [… read more]

Nov 092016
 
Almost half of intensivists feel severe burnout, report says

Almost half of critical care physicians report symptoms of severe burnout associated with their ICU work, according to a report and “call to action” from the Critical Care Societies Collaborative (CCSC). Symptoms of severe burnout were highest among pediatric critical care specialists, while 45% of intensivists caring for adults acknowledged severe burnout. Burnout symptoms include [… read more]

Nov 082016
 
CPAP did not reduce cardiovascular risk, especially when not worn

Nightly use of continuous positive airway pressure (CPAP) did not prevent cardiovascular events in high risk patients with obstructive sleep apnea, according to a large randomized trial. The SAVE study suggests that CPAP has no cardiovascular benefits for the millions of people using it less than 4 hours a night. However, those using CPAP for more [… read more]

Nov 022016
 
Long-term oxygen brought no benefits for moderate hypoxemia in COPD

In patients with COPD with exertional hypoxemia, long-term supplemental oxygen did not improve survival or quality of life in a multicenter randomized trial published in the New England Journal of Medicine. The NIH-funded study calls into question the current practice of routinely treating moderately hypoxemic COPD patients with supplemental oxygen, and the billions spent for it [… read more]

Oct 282016
 
Corticosteroids for sepsis didn't prevent septic shock (HYPRESS trial)

The idea that augmenting cortisol levels to normal or supranormal levels must be somehow beneficial in septic shock has a compelling basis in physiology and intuition. For physicians, injecting powerful synthetic hormones to restore homeostasis to save a dying patient is a seductive fulfillment of the scientist-savior fantasy. So intensivists were primed to believe the results of [… read more]